Naratriptan Viatris (Naratriptan Hydrochloride)

Naratriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of dilated vessels and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and any concomitant medications.

Safety data for naratriptan in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient before prescribing.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Naratriptan has a longer half‑life than some triptans, offering a prolonged duration of action, but it may have a slower onset of relief. Choice of triptan depends on individual response, speed of symptom relief needed, and tolerability profile.

Store the tablets at ambient temperature, below 25 °C, in the original blister pack or container. Keep them away from moisture, heat, and direct sunlight to maintain product stability.

Naratriptan Viatris is taken orally with a glass of water. It is usually taken as soon as migraine symptoms begin, and a second dose may be considered after at least four hours if the headache persists, following the prescriber’s guidance.

Serious risks include chest pain or tightness suggesting cardiac ischemia, severe hypertension, serotonin syndrome when combined with other serotonergic agents, and rare allergic reactions. Patients should seek immediate medical attention if these symptoms occur.

Naratriptan is contraindicated in patients with uncontrolled hypertension, a history of coronary artery disease, stroke, or peripheral vascular disease, as well as in those taking MAO inhibitors or ergot derivatives. It should also be avoided in individuals with known hypersensitivity to naratriptan.